Santhera制药公司报告,2025年稀有疾病药物开发资金稳定,进展顺利。 Santhera Pharmaceuticals reports stable finances and progress in rare disease drug development for 2025.

Santhera制药公司报告了其2025年的半年财政结果,重点介绍了临床发展方案的持续运作和进展。 Santhera Pharmaceuticals reported its half-year financial results for 2025, highlighting ongoing operations and progress in its clinical development programs. 该公司强调继续投资于研究与开发,其输油管道候选人的最新情况针对罕见疾病。 The company emphasized continued investment in research and development, with updates on its pipeline candidates targeting rare diseases. 财务报表反映了稳定的现金储备和符合战略目标的业务业绩。 Financial statements reflect stable cash reserves and operational performance in line with strategic goals. Santhera重申致力于推进神经肌肉病的治疗,同时指出其商业或监管前景没有重大变化。 Santhera reaffirmed its commitment to advancing therapies for neuromuscular conditions, while noting no major changes to its commercial or regulatory outlook.